CLEARBronchiectasis and Pseudomonas Aeruginosa Colonization Prevention Study for AZD0292 in Participants 12 and Older

This clinical trial is focused on testing a new treatment, AZD0292, for people aged 12 and older who have a lung condition called bronchiectasis and are chronically affected by a bacteria known as Pseudomonas aeruginosa. This bacteria can cause frequent worsening of lung symptoms, which can lead to a decline in lung health, impact daily life, and increase the risk of serious health issues. The study is important because it seeks to find an effective way to prevent these worsening episodes, which could significantly improve the lives of those living with this condition. Additionally, the treatment is also being explored in patients with cystic fibrosis who have similar bacterial colonization. In the study, participants will receive AZD0292 through an intravenous (IV) infusion, which means the medicine is delivered directly into the bloodstream. The study will compare the effects of AZD0292 given in two different doses to a placebo, which is a substance with no active medication. Researchers will look at how well the treatment works, its safety, and how the body processes the drug. While the study will primarily focus on patients with non-cystic fibrosis bronchiectasis, it will also include patients with cystic fibrosis as an exploratory group to understand the potential wider application of the treatment.